It mimics an intestinal hormone that tells the brain your stomach is full. Malignant colorectal carcinoma was diagnosed in 2 liraglutide-treated patients.In clinical trials, 6 cases of thyroid C-cell hyperplasia were reported among liraglutide-treated patients and 2 cases in the comparator-treated group (1.3 vs 1 case per 1000 patient-years).

Cerner Multum, Inc. "UK Summary of Product Characteristics."

Saxenda’s active ingredient is Liraglutide, which is a GLP-1 receptor agonist, and helps to suppress your appetite as well as reducing cravings for certain foods. Taking off weight and keeping it off may help improve conditions such as high blood pressure and high cholesterol levels.Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.Serious side effects may happen in people who take SaxendaTalk with your health care provider if you are not sure if you are pregnant or planning to become pregnant. Saxenda should not be used if there is a known hypersensitivity to liraglutide or any of the product components. Saxenda is used for weight loss in addition to diet and exercise in adults aged 18 and above who have a BMI of 30 or greater (obese) or a BMI of 27 and less than 30 (overweight) and weight related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, or breathing problems during sleep called obstructive sleep apnoea). O 03. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The clinical significance of this is unknown.While this drug has not been found to be directly nephrotoxic in animal studies or clinical trials, postmarketing reports of acute renal failure and worsening of Fatigue and asthenia were most commonly reported within the first 12 weeks and were often co-reported with gastrointestinal events.In clinical trials, 0.2% (6/3384) patients receiving liraglutide (the active ingredient contained in Saxenda) reported suicidal ideation and 1 attempted suicide.

Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. -Acute pancreatitis occurred in 0.3% (9/3291) of liraglutide-treated patients and 0.1% (1/1843) of placebo patients in clinical trials.

Major episodes of hypoglycemia have not been reported in clinical trials in which liraglutide was used as monotherapy, however, when used in combination with a sulfonylurea, hypoglycemia was very commonly reported.The most commonly reported adverse events for this drug when used for weight management have included nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase.

Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information -

Among all patients receiving this drug in combination with a sulfonylurea, symptomatic hypoglycemia occurred in 43.6% (48/110) of patients. -Acute gallbladder disease was reported more frequently in liraglutide-treated patients (1.5% versus 0.5%) during clinical trials. "Product Information. The recommended dose of Saxenda starts at just 0.6mg per day for the first week, then increases gradually each week until it reaches 3.0mg in week 5, at which point the patient should continue with a single 3.0mg dose each day.